Targets › INFLAV
1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 2; Infectious disease, Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on INFLAV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Baloxavir marboxil Polymerase acidic protein inhibitor | INFLAV, PB2 | Phase 3 | Influenza, Human; Influenza; Influenza Disease; Flu; Hematopoietic and Lymphoid Cell Neoplasm | Apr 2027 |
Influenza, Human (1) Influenza (1) Influenza Disease; Flu (1) Hematopoietic and Lymphoid Cell Neoplasm (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.